SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
1-Year Return
18.23%
This Quarter Return
+0.83%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.45B
AUM Growth
+$173M
(+14%)
Cap. Flow
+$220M
Cap. Flow
% of AUM
15.19%
Top 10 Holdings %
Top 10 Hldgs %
47.24%
Holding
102
New
27
Increased
19
Reduced
27
Closed
7
Top Buys
| 1 |
Krystal Biotech
KRYS
|
$66.1M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$34.8M |
| 3 |
UroGen Pharma
URGN
|
$29.9M |
| 4 |
Elevance Health
ELV
|
$27.2M |
| 5 |
UnitedHealth
UNH
|
$26.9M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$21.7M |
| 2 |
Insmed
INSM
|
$20.3M |
| 3 |
Hologic
HOLX
|
$18.7M |
| 4 |
Merus
MRUS
|
$18.2M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$18M |
Sector Composition
| 1 | Healthcare | 99.87% |
| 2 | Consumer Staples | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Integra LifeSciences
IART
$1.25B
| $17M | 1.13% |
1,387,818
+315,614
| +29% | +$3.87M |
|
27
Axogen
AXGN
$735M
| $15.8M | 1.05% |
1,459,395
+13,278
| +0.9% | +$144K |
|
28
Mirum Pharmaceuticals
MIRM
$3.82B
| $15.2M | 1.01% |
+298,696
| New | +$15.2M |
|
29
Ascendis Pharma
ASND
$12.5B
| $14.7M | 0.97% |
85,000
+28,700
| +51% | +$4.95M |
|
30
Inspire Medical Systems
INSP
$2.56B
| $14.1M | 0.94% |
109,000
+70,000
| +179% | +$9.08M |
|
31
Twist Bioscience
TWST
$1.55B
| $13M | 0.86% |
+354,401
| New | +$13M |
|
32
Pharvaris
PHVS
$1.48B
| $12.9M | 0.85% |
732,968
-81,684
| -10% | -$1.44M |
|
33
Inhibikase Therapeutics
IKT
$124M
| $12.3M | 0.82% |
6,325,000
| – | – |
|
34
Rigel Pharmaceuticals
RIGL
$742M
| $12.3M | 0.82% |
658,145
-472,534
| -42% | -$8.85M |
|
|
EDAP
35
EDAP TMS
EDAP
$94.2M
| $12.1M | 0.8% |
7,309,254
| – | – |
|
|
THTX
36
Theratechnologies
THTX
$150M
| $11.3M | 0.75% |
4,801,376
| – | – |
|
37
Syndax Pharmaceuticals
SNDX
$1.47B
| $10.2M | 0.68% |
1,092,110
+275,500
| +34% | +$2.58M |
|
38
C4 Therapeutics
CCCC
$194M
| $9.98M | 0.66% |
6,978,942
| – | – |
|
39
Enovis
ENOV
$1.84B
| $9.88M | 0.65% |
+315,000
| New | +$9.88M |
|
40
Nuvalent
NUVL
$5.83B
| $9.54M | 0.63% |
125,000
-89,357
| -42% | -$6.82M |
|
41
Establishment Labs
ESTA
$1.13B
| $9.05M | 0.6% |
+211,900
| New | +$9.05M |
|
42
Jasper Therapeutics
JSPR
$44.2M
| $8.29M | 0.55% |
1,494,420
| – | – |
|
43
Arcellx
ACLX
$4.03B
| $8.1M | 0.54% |
123,031
-30,000
| -20% | -$1.98M |
|
|
JBIO
44
Jade Biosciences, Inc. Common Stock
JBIO
$254M
| $7.96M | 0.53% |
+796,744
| New | +$7.96M |
|
|
45
Insmed
INSM
$30.7B
| $7.32M | 0.49% |
72,772
-201,500
| -73% | -$20.3M |
|
46
AnaptysBio
ANAB
$613M
| $7.13M | 0.47% |
321,040
+218,988
| +215% | +$4.86M |
|
47
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $7.05M | 0.47% |
254,689
-214,811
| -46% | -$5.94M |
|
|
SION
48
Sionna Therapeutics, Inc. Common Stock
SION
$1.06B
| $6.52M | 0.43% |
376,000
+136,000
| +57% | +$2.36M |
|
|
CBIO
49
Crescent Biopharma, Inc. Common Stock
CBIO
$198M
| $6.46M | 0.43% |
+400,000
| New | +$6.46M |
|
50
Iovance Biotherapeutics
IOVA
$901M
| $5.61M | 0.37% |
3,261,707
-4,523,293
| -58% | -$7.78M |
|